CN115379848A - 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂 - Google Patents

靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂 Download PDF

Info

Publication number
CN115379848A
CN115379848A CN202180025582.7A CN202180025582A CN115379848A CN 115379848 A CN115379848 A CN 115379848A CN 202180025582 A CN202180025582 A CN 202180025582A CN 115379848 A CN115379848 A CN 115379848A
Authority
CN
China
Prior art keywords
binding moiety
tumor
disease
lrrc15
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180025582.7A
Other languages
English (en)
Chinese (zh)
Inventor
H·D·乌尔默特
N·佩克豪斯
L·毛
R·D·达莫伊索
C·斯托里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN115379848A publication Critical patent/CN115379848A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180025582.7A 2020-04-01 2021-03-31 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂 Pending CN115379848A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003598P 2020-04-01 2020-04-01
US63/003,598 2020-04-01
PCT/US2021/025054 WO2021202642A2 (en) 2020-04-01 2021-03-31 Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease

Publications (1)

Publication Number Publication Date
CN115379848A true CN115379848A (zh) 2022-11-22

Family

ID=77929889

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025582.7A Pending CN115379848A (zh) 2020-04-01 2021-03-31 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂

Country Status (9)

Country Link
US (1) US20230133775A1 (https=)
EP (1) EP4125991A4 (https=)
JP (1) JP2023520392A (https=)
KR (1) KR20220161395A (https=)
CN (1) CN115379848A (https=)
AU (1) AU2021246485A1 (https=)
BR (1) BR112022019758A2 (https=)
CA (1) CA3174263A1 (https=)
WO (1) WO2021202642A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975036B (zh) * 2022-08-18 2023-06-09 北京诺赛国际医学研究院 包含干细胞的药物组合物及其治疗癌症的用途
WO2024081729A2 (en) * 2022-10-12 2024-04-18 Mythic Therapeutics, Inc. Lrrc-15-binding protein constructs and uses thereof
TW202434310A (zh) * 2023-01-27 2024-09-01 日商第一三共股份有限公司 抗lrrc15抗體
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025160129A1 (en) * 2024-01-23 2025-07-31 The Regents Of The University Of California Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025264059A1 (ko) * 2024-06-20 2025-12-26 주식회사 에디스바이오텍 Lrrc15에 특이적으로 결합하는 항체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219618A (zh) * 2016-01-21 2019-01-15 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
US10195209B2 (en) * 2015-11-30 2019-02-05 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862770B2 (en) * 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
SG10201900002QA (en) * 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
JP2016056165A (ja) * 2014-08-12 2016-04-21 学校法人藤田学園 抗α６β４インテグリン抗体を利用したがん又は腫瘍の診断又は治療のための抗体製剤及び抗体キット
AU2016365114A1 (en) * 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
WO2018083087A2 (en) * 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
CN112041337B (zh) * 2018-04-16 2025-01-07 日本医事物理股份有限公司 修饰抗体、及放射性金属标记抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195209B2 (en) * 2015-11-30 2019-02-05 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
CN109219618A (zh) * 2016-01-21 2019-01-15 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES W. PURCELL等: "LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates", CANCER RESEARCH, vol. 78, no. 14, 15 March 2018 (2018-03-15), pages 3 - 4 *

Also Published As

Publication number Publication date
EP4125991A2 (en) 2023-02-08
WO2021202642A2 (en) 2021-10-07
KR20220161395A (ko) 2022-12-06
CA3174263A1 (en) 2021-10-07
JP2023520392A (ja) 2023-05-17
US20230133775A1 (en) 2023-05-04
WO2021202642A3 (en) 2021-11-11
AU2021246485A1 (en) 2022-11-17
BR112022019758A2 (pt) 2023-01-31
EP4125991A4 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
CN115379848A (zh) 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂
US12383637B2 (en) Therapeutic agents and uses thereof
KR102464774B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
US11427648B2 (en) Anti-CD146 antibodies and uses thereof
KR102628557B1 (ko) 폐암의 치료를 위한 항-pd-1 항체
ES2341625T3 (es) Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas.
JP7368856B2 (ja) Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
US12151004B2 (en) Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
Arbuznikova et al. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu] Lu-PSMA-617 for prostate cancer-from bench to bedside
US20240216554A1 (en) Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
Sharma et al. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment
US20220143228A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
Li et al. Single domain Camelid antibody fragments for molecular imaging and therapy of cancer
EP4661919A1 (en) Methods for treating glioblastoma
US11357874B2 (en) Tumor targeted radionuclide therapy and molecular imaging of HER2+ cancers and other neoplasms
KR20230128271A (ko) 고형 암의 치료를 위한 her3 방사선면역요법
Canevari et al. Ovarian carcinoma therapy with monoclonal antibodies
US12447218B1 (en) Radioconjugates directed to MHC-complexed antigens in cancer
Kondo HER2-targeted Theranostic Radioimmunoconjugates for SPECT Imaging and α-particle Radioimmunotherapy of HER2-positive Breast Cancer
Sharma et al. A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET
WO2025160129A1 (en) Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells
KR20250147080A (ko) 방사성동위원소가 표지된 항-her2 항체-킬레이터 접합체, 이를 포함하는 약학적 조성물 및 이의 제조방법
US20230390424A1 (en) Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
MOROZ PRECLINICAL TESTING OF NEW MODALITIES FOR PET VISUALIZATION AND TREATMENT OF RAS-DRIVEN CANCERS
Salouti et al. Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination